Current Drug Targets
Title:Editorial
Volume: 20 Issue: 2
Author(s): Ahmad Hatim Sulaiman and Ramli Musa
Affiliation:
Export Options
About this article
Cite this article as:
Sulaiman Hatim Ahmad and Musa Ramli , Editorial, Current Drug Targets 2019; 20 (2) . https://dx.doi.org/10.2174/138945012002181203145147
DOI https://dx.doi.org/10.2174/138945012002181203145147 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Minocycline: Neuroprotective Mechanisms in Parkinsons Disease
Current Pharmaceutical Design Pharmacogenetic Approach to Treating Drug Dependence: Serotonin Transporter Gene (SLC6A4) Promoter Polymorphisms as Treatment Predictors in Jordanian Arabs
Current Pharmacogenomics and Personalized Medicine Towards a Unified Theory of Calmodulin Regulation (Calmodulation) of Voltage-Gated Calcium and Sodium Channels
Current Molecular Pharmacology Chronic Paroxetine Treatment: Effects on Other Non-Serotonergic Neurotransmitter Systems
CNS & Neurological Disorders - Drug Targets Prognostic and Predictive Molecular Markers in Cutaneous Malignant Melanoma: The First Step Toward Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Inflammation as the Common Biological Link Between Depression and Cardiovascular Diseases: Can Carnosine Exert a Protective Role?
Current Medicinal Chemistry Cognitive Impairment with Vascular Impairment and Degeneration
Current Neurovascular Research Cardiac Effect of Cholinesterase Inhibitors Used in Alzheimers Disease - from Basic Research to Bedside
Current Alzheimer Research Central Nervous System Depressants and Risk of Hospitalization due to Community-Acquired Pneumonia in very Old Patients
Current Drug Safety Ceramide and Sphingosine-1-Phosphate in Cell Death Pathways : Relevance to the Pathogenesis of Alzheimer's Disease
Current Alzheimer Research The Role of Viruses in Neurodegenerative and Neurobehavioral Diseases
CNS & Neurological Disorders - Drug Targets Quantitative Investigation of Biomolecular Interactions in Crowded Media by Fluorescence Spectroscopy, a Good Choice
Current Protein & Peptide Science Phosphodiesterase 10 Inhibitors: New Disease Modifying Drugs for Parkinson’s Disease?
Current Medicinal Chemistry P-glycoprotein Inhibition: The Past, the Present and the Future
Current Drug Metabolism Knockdown of miR-124 Reduces Depression-like Behavior by Targeting CREB1 and BDNF
Current Neurovascular Research Editorial
Current Medicinal Chemistry Dual Inhibition of DPP-4 and Cholinesterase Enzymes by the Phytoconstituents of the Ethanolic Extract of Prosopis cineraria Pods: Therapeutic Implications for the Treatment of Diabetes-associated Neurological Impairments
Current Alzheimer Research Diet and Neurocognition in Mood Disorders - An Overview of the Overlooked
Current Pharmaceutical Design Analysis of Pralidoxime in Serum, Brain and CSF of Rats
Medicinal Chemistry The Effects of Cognitive Speed of Processing Training Among Older Adults with Psychometrically- Defined Mild Cognitive Impairment
Current Alzheimer Research